OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Grigg on the Results of the CheckMate-214 Trial in RCC

January 7th 2021

Claud M. Grigg, Jr., MD, discusses the results of the CheckMate-214 trial in renal cell carcinoma.

Dr. Lin on the Emergence of CAR T-Cell Therapy in Multiple Myeloma

January 7th 2021

Yi Lin, MD, PhD, discusses the emergence of CAR T-cell therapy in multiple myeloma.

Dr. Chiorean on the Role of Genetic Testing in Pancreatic Cancer

January 7th 2021

Elena Gabriela Chiorean, MD, discusses the role of genetic testing in pancreatic cancer.

Dr. Janjigian on the Expanding Treatment Armamentarium in HER2+ Gastric Cancer

January 7th 2021

Yelena Y. Janjigian, MD, discusses the expanding treatment armamentarium in HER2-positive gastric cancer.

Dr. Patel on a Subgroup Analysis of the NAPOLI-1 Trial in Pancreatic Cancer

January 7th 2021

Reema A. Patel, MD, discusses the results of a subgroup analysis from the NAPOLI-1 trial in pancreatic cancer.

Dr. Sweet on Key Findings From the OPTIC Trial With Ponatinib in CML

January 7th 2021

Kendra Sweet, MD, discusses key findings from the OPTIC trial with ponatinib in chronic myeloid leukemia.

Dr. Ailawadhi on the Potential Role of Melflufen in Multiple Myeloma

January 7th 2021

Sikander Ailawadhi, MD, discusses the potential role of melflufen in multiple myeloma.

Dr. McGregor on the Focus of Future Research Efforts in RCC

January 7th 2021

Bradley McGregor, MD, discusses the focus of future research efforts in renal cell carcinoma.

Dr. O'Shaughnessy on the Rationale for the MonarchE Trial in Breast Cancer

January 7th 2021

Joyce A. O'Shaughnessy, MD, discusses the rationale for the monarchE trial in breast cancer.

Dr. Dhir on Modifying Treatment for Adults Versus Pediatric Patients With Epithelioid Sarcoma

January 6th 2021

Aditi Dhir, MD, discusses modifying treatment for adults versus pediatric patients with epithelioid sarcoma.

Dr. Bekaii-Saab on Incorporating Mechanisms of Resistance Into Treatment Selection in HCC

January 6th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses incorporating potential mechanisms of resistance into treatment selection in hepatocellular carcinoma.

Dr. Bannerji on the Toxicity Profile of Odronextamab in Non-Hodgkin Lymphoma

January 6th 2021

Rajat Bannerji, MD, PhD, discusses the toxicity profile of odronextamab in non-Hodgkin lymphoma.

Dr. Herbst on the Approval of Adjuvant Osimertinib in EGFR+ NSCLC

January 6th 2021

Roy S. Herbst, MD, PhD, discusses the approval of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.

Dr. Luke on Predictive Versus Prognostic Biomarkers in Melanoma

January 6th 2021

Jason J. Luke, MD, FACP, compares predictive and prognostic biomarkers in melanoma.

Dr. Trent on the Role of Adjuvant Imatinib in GIST

January 6th 2021

Jonathan C. Trent, MD, PhD, discusses the role of adjuvant imatinib in gastrointestinal stromal tumors.

Dr. Sequist on the Importance of Broad Molecular Testing in Lung Cancer

January 5th 2021

Lecia V. Sequist, MD, MPH, discusses the importance of implementing broad molecular testing in lung cancer.

Dr. Gupta on Developing Biomarkers of Lack of Response in Urothelial Carcinoma

January 5th 2021

Shilpa Gupta, MD, discusses the need to develop biomarkers of lack of response to immunotherapy in urothelial carcinoma.

Dr. Ailawadhi on the Integration of Selinexor in Relapsed/Refractory Multiple Myeloma

January 5th 2021

Sikander Ailawadhi, MD, discusses the integration of selinexor into the treatment landscape of relapsed/refractory multiple myeloma.

Dr. Andorsky on the Results of a Subgroup Analysis of the MAGNIFY Trial in NHL

January 5th 2021

David J. Andorsky, MD, discusses the results of a subgroup analysis of the phase 3b MAGNIFY trial in relapsed/refractory non-Hodgkin lymphoma.

Dr. Barr on Exploring U2 Plus Venetoclax in Relapsed/Refractory CLL

January 4th 2021

Paul M. Barr, MD, discusses exploring umbralisib plus ublituximab plus venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia.